TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from PainReform ( (PRFX) ).
On November 25, 2025, PainReform Ltd. announced its upcoming Annual General Meeting of Shareholders scheduled for December 30, 2025, in Tel Aviv, Israel. The meeting’s agenda includes significant proposals such as the re-election of Dr. Ehud Geller to the Board, a name change to PRF Ltd., an increase in authorized share capital, a reverse stock split, and the re-appointment of Kesselman & Kesselman as the company’s auditors. These proposals, if approved, could impact the company’s operational structure and market identity, potentially influencing shareholder value and market perception.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Underperform.
PainReform faces substantial financial hurdles, primarily due to its lack of revenue and persistent losses, making its financial performance the most significant negative factor. Technical analysis reflects a neutral to slightly bearish outlook, while valuation metrics underscore the company’s financial struggles with a negative P/E ratio. Overall, the stock presents high risks without notable strengths to offset these concerns.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of reformulated pain medications. The company is headquartered in Tel Aviv, Israel, and aims to enhance the efficacy and safety of existing pain treatments through innovative drug delivery systems.
Average Trading Volume: 376,274
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.77M
See more insights into PRFX stock on TipRanks’ Stock Analysis page.